Frumento, Nicole, Porter, Catharine ORCID: https://orcid.org/0000-0003-1851-0677, Euden, Joanne ORCID: https://orcid.org/0000-0002-2844-6878, Varley, Melanie ORCID: https://orcid.org/0000-0002-5702-9205, Raisanen, Lawrence, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Bodman, Craig, Carroll, Miles, Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609, Cicconi, Paola, Dagley, Vivien, Govender, Melissa, Griffin, Sian, Harris, Debbie ORCID: https://orcid.org/0000-0002-7073-7724, Hill, Adrian V. S., Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631, Jeffery, Katie, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Laidlaw, Stephen M., Meacham, Georgina, Nixon, Lisette ORCID: https://orcid.org/0000-0002-1270-6970, Ottensmeier, Christian H., Pringle, Shirley, Rolt, Jordan, Shier, Susannah, Tangney, Rebecca, Thomas-Jones, Emma ORCID: https://orcid.org/0000-0001-7716-2786, Tridgell, Alexander, Walker, Victoria, Wilson, Keith, Barnes, Eleanor and Tuthill, Mark
2026.
Co-administration of the long-acting monoclonal antibody AZD7442 and bivalent Ancestral/BA.1 vaccination is well-tolerated in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus: the results of the multicentre, open-label, phase II randomised controlled, RAPID-PROTECTION trial.
Nature Communications
10.1038/s41467-026-78637-z
|
|
PDF
- Accepted Post-Print Version
Available under License Creative Commons Attribution. Download (2MB) |
Abstract
Immunocompromised individuals remain at risk of severe COVID-19. This multicentre, open-label, phase II randomised controlled trial evaluated the safety, pharmacokinetics and immunogenicity of co-administering the long-acting monoclonal antibody AZD7442 with a bivalent (Ancestral/BA.1) mRNA/LNP SARS-CoV-2 vaccine. A total of 139 immunocompromised adults received AZD7442 followed 28 days later by vaccination. AZD7442 was well tolerated, with no serious adverse events. Serum AZD7442 concentrations peaked at day 28 and remained detectable across disease cohorts at day 180. Anti-Spike antibody responses increased after AZD7442 and reached their highest levels after vaccination. Although binding antibodies against Omicron variants increased post-vaccination, neutralisation of Omicron remained limited after both AZD7442 and vaccination. Vaccination preferentially boosted antibodies targeting S2, the S1 N-terminal domain and receptor-binding domain epitopes not bound by AZD7442, and increased S2-specific memory B cells. Vaccine-induced T-cell responses were cross-reactive between ancestral and Omicron variants. Our findings support consideration of combined antibody and vaccine strategies in future therapeutic antibody development. The trial is registered with the International Standard Randomised Controlled Trial Number registry (ISRCTN53507177).
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | In Press |
| Schools: | Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR) |
| Publisher: | Nature Research |
| ISSN: | 2041-1723 |
| Date of First Compliant Deposit: | 18 November 2026 |
| Date of Acceptance: | 24 September 2026 |
| Last Modified: | 18 Nov 2026 14:45 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/191040 |
Actions (repository staff only)
![]() |
Edit Item |





Dimensions
Dimensions